ENG/中
老虎證券
市场
行情
24/7新闻
产品
Cash Boost账户
期权
A股通
港股
固定票息票据
美股
ETF
基金超市
美国国债
新加坡股
期货
Tiger BOSS Debit Card
老虎钱袋子
功能
经纪人
定投
CPF/SRS 投资
专栏
美股碎股
TigerAI
费用
综合账户
股票与ETF
期权、窝轮与牛熊证
期货
债券
基金超市
Cash Boost
股票与ETF
融资利率
活动
帮助
账户操作
如何开户
开户文件
账户类型
资金与转仓
入金
DDA快捷入金
出金
转入股票
转出股票
货币兑换
产品与交易
可交易产品
订单类型
交易规则
申报
融资融券
保证金与杠杆
风险管理
做空风险
基金超市
基金开户与交易
Cash Boost账户
Cash Boost 账户FAQ
如何开通 Cash Boost 账户
如何用Cash Boost 账户交易
如何绑定CDP证券账户
Tiger Boss Debit Card
常见问题
费用说明
如何充值
如何使用我的Debit card
账单报表
账单报表
股息（分红）
机构
Tiger Fund Management
机构服务
财富及资产管理人
自营交易机构
介绍经纪商
三方服务商
老虎API平台
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Filana Therapeutics
1.76
+0.1500
9.32%
盤後：
1.75
-0.0100
-0.57%
19:58 EDT
成交量：
99.12萬
成交額：
168.92萬
市值：
8,502.19萬
市盈率：
-0.93
高：
1.77
開：
1.64
低：
1.58
收：
1.61
52周最高：
4.98
52周最低：
1.37
股本：
4,830.79萬
流通股本：
4,347.52萬
量比：
2.80
換手率：
2.28%
股息：
- -
股息率：
- -
每股收益(TTM):
-1.8836
每股收益(LYR):
-1.8836
淨資產收益率：
-82.66%
總資產收益率：
-27.23%
市淨率：
1.14
市盈率(LYR):
-0.93
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字：
Filana Therapeutics
交易所：
NASDAQ
成立時間：
1998
員工人數：
19
公司地址：
6801 N. Capital of Texas Highway,Building 1,Austin,Texas,United States
官網：
http://www.filanatx.com
郵編：
78731
電話：
512 501 2444
傳真：
- -
簡介：
Filana Therapeutics, Inc.於1998年5月在特拉華州註冊成立。該公司是一家總部位於德克薩斯州奧斯汀的臨床階段生物技術公司。公司致力於開發變革性藥物，以改善中樞神經系統疾病患者的生活，重點關注如結節性硬化症相關癲癇等與細絲蛋白A失調或過表達相關的疾病。其科學方法的核心在於調節大腦中這一關鍵蛋白質的活性。公司的主要在研治療藥物simufilam是一種口服的proprietary小分子藥物，最初為阿爾茨海默病而開發。在阿爾茨海默病項目於2025年年中全面終止后，公司重新調整了工作重心。Simufilam目前正被研究用於治療結節性硬化症相關癲癇，其靶點為細絲蛋白A——這是一種獨立於傳統mTOR通路的新型作用機制。臨床前研究表明，這種潛在的首創型細絲蛋白A調節劑可能改善導致結節性硬化症患者癲癇發作的神經元過度生長和畸形。公司將繼續探索simufilam在臨床前實驗显示可能具有療效的其他潛在適應症，包括中樞神經系統相關及其他領域。
董事
名稱
職位
Claude Nicaise
Chairman of the Board and Director
Richard J. Barry
Chief Executive Officer and Director and President
Dawn Carter Bir
Director
Michael J. O'donnell
Director
Patrick J. Scannon
Director
Pierre Gravier
Director
Robert Anderson
Director
Robert Z. Gussin
Director
股東
名稱
職位
Richard J. Barry
Chief Executive Officer and Director and President
Eric J. Schoen
Chief Financial Officer
R. Christopher Cook
Chief Operating and Legal Officer
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/FLNA/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"FLNA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FLNA\",,,,,undefined,":{"symbol":"FLNA","market":"US","secType":"STK","nameCN":"Filana Therapeutics","latestPrice":1.76,"timestamp":1776369600000,"preClose":1.61,"halted":0,"volume":991206,"hourTrading":{"tag":"盘后","latestPrice":1.75,"preClose":1.76,"latestTime":"19:58 EDT","volume":144946,"amount":255089.7897,"timestamp":1776383907945,"change":-0.01,"changeRate":-0.005682,"amplitude":0.028409},"delay":0,"changeRate":0.09316770186335398,"floatShares":43475193,"shares":48307896,"eps":-1.883615,"marketStatus":"未開盤","change":0.15,"latestTime":"04-16 16:00:00 EDT","open":1.64,"high":1.77,"low":1.58,"amount":1689206.9214816,"amplitude":0.118012,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.883615,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1776412800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":1.61,"preHourTrading":{"tag":"盘前","latestPrice":1.64,"preClose":1.61,"latestTime":"09:25 EDT","volume":6721,"amount":10858.508089,"timestamp":1776345900235,"change":0.03,"changeRate":0.018634,"amplitude":0.024845},"postHourTrading":{"tag":"盘后","latestPrice":1.75,"preClose":1.76,"latestTime":"19:58 EDT","volume":144946,"amount":255089.7897,"timestamp":1776383907945,"change":-0.01,"changeRate":-0.005682,"amplitude":0.028409},"volumeRatio":2.79661,"impliedVol":0.5379,"impliedVolPercentile":0.0385},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FLNA\",,,,,undefined,":{"symbol":"FLNA","floatShares":43475193,"roa":"-27.23%","roe":"-82.66%","lyrEps":-1.883615,"volumeRatio":2.79661,"shares":48307896,"dividePrice":0,"high":1.77,"amplitude":0.118012,"preClose":1.61,"low":1.58,"week52Low":1.37,"pbRate":"1.14","week52High":4.98,"institutionHeld":0.3447,"latestPrice":1.76,"eps":-1.883615,"divideRate":0,"volume":991206,"delay":0,"ttmEps":-1.883615,"open":1.64,"prevYearClose":1.98,"prevWeekClose":1.64,"prevMonthClose":1.69,"prevQuarterClose":1.69,"fiveDayClose":1.72,"twentyDayClose":1.91,"sixtyDayClose":1.99},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FLNA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-03-12","symbol":"FLNA","fiscalQuarterEnding":"2025/12","expectedEps":null,"name":null,"time":"盤前","type":"earning","dateTimestamp":1773288000000,"reportTimeType":"pre","actualEps":-0.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FLNA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FLNA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1759809600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/FLNA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"FLNA","date":"2026-04-15","current":-0.934374,"percent":1,"low":-1.062027,"twenty":-1.004677,"median":-0.929274,"eighty":-0.886793,"high":-0.844312,"avg":-0.942398,"sd":0.064318,"marketCap":76809554},"quantilePoints":[{"date":"2026-03-13","current":-1.035476,"twenty":-1.018822,"median":-0.993842,"eighty":-0.968861,"marketCap":94200397},{"date":"2026-03-20","current":-0.971755,"twenty":-1.052469,"median":-1.035476,"eighty":-0.980251,"marketCap":88403449},{"date":"2026-03-27","current":-0.939894,"twenty":-1.035476,"median":-0.99034,"eighty":-0.956117,"marketCap":85504975},{"date":"2026-04-02","current":-0.913343,"twenty":-1.035476,"median":-0.971755,"eighty":-0.913343,"marketCap":83089581},{"date":"2026-04-10","current":-0.913343,"twenty":-1.014236,"median":-0.950514,"eighty":-0.897413,"marketCap":83089581},{"date":"2026-04-15","current":-0.844312,"twenty":-1.004677,"median":-0.929274,"eighty":-0.886793,"marketCap":76809554}],"updateTime":1776390068182},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":107567,"yearFounded":1998,"employeeNum":19,"address":"6801 N. Capital of Texas Highway,Building 1,Austin,Texas,United States","zipCode":"78731","officePhone":"512 501 2444","fiscalYearEnd":"12-31"},"stockCompanyDetail":{"websiteUrl":"http://www.filanatx.com","stockEarnings":[{"period":"1week","weight":0.0233},{"period":"1month","weight":-0.12},{"period":"3month","weight":-0.1373},{"period":"6month","weight":-0.5907},{"period":"1year","weight":0.2571},{"period":"ytd","weight":-0.1111}],"compareEarnings":[{"period":"1week","weight":0.032},{"period":"1month","weight":0.046},{"period":"3month","weight":0.0145},{"period":"6month","weight":0.0561},{"period":"1year","weight":0.3348},{"period":"ytd","weight":0.0289}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Filana Therapeutics, Inc.於1998年5月在特拉華州註冊成立。該公司是一家總部位於德克薩斯州奧斯汀的臨床階段生物技術公司。公司致力於開發變革性藥物，以改善中樞神經系統疾病患者的生活，重點關注如結節性硬化症相關癲癇等與細絲蛋白A失調或過表達相關的疾病。其科學方法的核心在於調節大腦中這一關鍵蛋白質的活性。公司的主要在研治療藥物simufilam是一種口服的proprietary小分子藥物，最初為阿爾茨海默病而開發。在阿爾茨海默病項目於2025年年中全面終止后，公司重新調整了工作重心。Simufilam目前正被研究用於治療結節性硬化症相關癲癇，其靶點為細絲蛋白A——這是一種獨立於傳統mTOR通路的新型作用機制。臨床前研究表明，這種潛在的首創型細絲蛋白A調節劑可能改善導致結節性硬化症患者癲癇發作的神經元過度生長和畸形。公司將繼續探索simufilam在臨床前實驗显示可能具有療效的其他潛在適應症，包括中樞神經系統相關及其他領域。","yearOnYearQuotes":[{"month":1,"riseRate":0.576923,"avgChangeRate":0.143985},{"month":2,"riseRate":0.461538,"avgChangeRate":0.031957},{"month":3,"riseRate":0.423077,"avgChangeRate":-0.001874},{"month":4,"riseRate":0.615385,"avgChangeRate":0.059045},{"month":5,"riseRate":0.44,"avgChangeRate":0.038503},{"month":6,"riseRate":0.44,"avgChangeRate":-0.019669},{"month":7,"riseRate":0.48,"avgChangeRate":0.007146},{"month":8,"riseRate":0.5,"avgChangeRate":0.01628},{"month":9,"riseRate":0.615385,"avgChangeRate":0.114687},{"month":10,"riseRate":0.423077,"avgChangeRate":-0.039373},{"month":11,"riseRate":0.576923,"avgChangeRate":-0.009282},{"month":12,"riseRate":0.346154,"avgChangeRate":0.016148}],"exchange":"NASDAQ","name":"Filana Therapeutics","nameEN":"Filana Therapeutics"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"FLNA\",market:\"US\",,,undefined,":{"directors":[{"name":"Claude Nicaise","position":"Chairman of the Board and Director"},{"name":"Richard J. Barry","position":"Chief Executive Officer and Director and President"},{"name":"Dawn Carter Bir","position":"Director"},{"name":"Michael J. O'donnell","position":"Director"},{"name":"Patrick J. Scannon","position":"Director"},{"name":"Pierre Gravier","position":"Director"},{"name":"Robert Anderson","position":"Director"},{"name":"Robert Z. Gussin","position":"Director"}],"executives":[{"name":"Richard J. Barry","position":"Chief Executive Officer and Director and President"},{"name":"Eric J. Schoen","position":"Chief Financial Officer"},{"name":"R. Christopher Cook","position":"Chief Operating and Legal Officer"}]}}}